Gallium-68 DOTATATE

Diagnostic / Nuclear Medicine

Also known as: 68Ga-DOTATATE, NETSPOT, Ga-68 DOTATATE, Gallium DOTATATE

Somatostatin Receptor Imaging AgentsResearch phase: ApprovedRegulatory: FDA-approved 2016 (NETSPOT) for PET imaging of somatostatin receptor-positive NETs.

Mechanism

Gallium-68 DOTATATE (NETSPOT) is an FDA-approved PET imaging agent for detecting neuroendocrine tumors. It binds to somatostatin receptors that are overexpressed on these tumors.

Technical detail

Gallium-68 DOTATATE is a radiolabeled somatostatin analog (DOTA-Tyr3-octreotate) chelated with 68Ga for PET/CT imaging. It binds SST2 receptors with high affinity, enabling detection of somatostatin receptor-positive neuroendocrine tumors with superior sensitivity and specificity compared to conventional 111In-DTPA-octreotide (OctreoScan) SPECT imaging.

Evidence

Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors
Crown A, Rocha FG, Raghu P, Lin B, Funk G, Alseidi A, Hubka M, Rosales J, Lee M, Kennecke H (2020) — J Surg Oncol — PMID: 31853990
In a 101-patient NET cohort, initial Ga-68 DOTATATE PET/CT changed management in 35.6% of patients, altered operative plans in 50% of those referred for surgery, and changed systemic therapy or PRRT-related decisions in multiple cases.
strong

Build a personalized protocol with Gallium-68 DOTATATE →